Addex Therapeutics Valuation
| ADXN Stock | CHF 0.06 0 6.01% |
Addex Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Addex Therapeutics from analyzing the firm fundamentals such as operating margin of (17.07) %, and Return On Equity of -2.03 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Addex Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Addex Therapeutics is based on 3 months time horizon. Increasing Addex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Addex stock is determined by what a typical buyer is willing to pay for full or partial control of Addex Therapeutics. Since Addex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Addex Stock. However, Addex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.06 | Real 0.055 | Hype 0.06 |
The intrinsic value of Addex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Addex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Addex Therapeutics helps investors to forecast how Addex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Addex Therapeutics more accurately as focusing exclusively on Addex Therapeutics' fundamentals will not take into account other important factors: Addex Therapeutics Total Value Analysis
Addex Therapeutics is presently anticipated to have takeover price of 2.92 M with market capitalization of 28.26 M, debt of 194.32 K, and cash on hands of 20.48 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Addex Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.92 M | 28.26 M | 194.32 K | 20.48 M |
Addex Therapeutics Investor Information
The company has price-to-book (P/B) ratio of 1.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Addex Therapeutics recorded a loss per share of 0.53. The entity last dividend was issued on the 26th of July 2022. Based on the key indicators related to Addex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Addex Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Addex Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Addex Therapeutics has an asset utilization ratio of 12.94 percent. This indicates that the Company is making ₣0.13 for each dollar of assets. An increasing asset utilization means that Addex Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Addex Therapeutics Ownership Allocation
Addex Therapeutics holds a total of 115.35 Million outstanding shares. Addex Therapeutics shows 8.96 percent of its outstanding shares held by insiders and 9.31 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Addex Therapeutics Profitability Analysis
The company reported the revenue of 2.92 M. Net Loss for the year was (15.35 M) with loss before overhead, payroll, taxes, and interest of (9.69 M).About Addex Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Addex Therapeutics. We calculate exposure to Addex Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Addex Therapeutics's related companies.Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. ADDEX N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 17 people.
8 Steps to conduct Addex Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Addex Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Addex Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Addex Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Addex Therapeutics' revenue streams: Identify Addex Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Addex Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Addex Therapeutics' growth potential: Evaluate Addex Therapeutics' management, business model, and growth potential.
- Determine Addex Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Addex Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.